Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Grand Pharmaceutical Group Limited ( (HK:0512) ) just unveiled an update.
Grand Pharmaceutical Group Limited has announced that its nuclear medicine R&D and production base in Chengdu has obtained a Class A ‘Radiation Safety License’ and will soon commence operations. This development marks a significant milestone in the company’s strategy to become a global leader in nuclear medicine, enhancing its capabilities in isotope production and nuclear medicine preparation. The base, with an investment of over RMB 3 billion, features advanced technological breakthroughs and aims to set new safety benchmarks in the industry. It will support the company’s global strategy by providing a closed-loop system for R&D, production, and sales, and will contribute to the development of high-value nuclear medicine products, strengthening its position in the global market.
More about Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited operates in the pharmaceutical industry, focusing on nuclear medicine research and development. The company is known for its innovative approaches in nuclear medicine, particularly in anti-tumor diagnosis and treatment, and aims to establish a strong global presence in this field.
Average Trading Volume: 18,893,297
Technical Sentiment Signal: Buy
Current Market Cap: HK$29.92B
For a thorough assessment of 0512 stock, go to TipRanks’ Stock Analysis page.